| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 6.744 | 24.244 | 12.451 | 11.790 | 10.062 |
| Total Income - EUR | - | - | - | - | - | 6.744 | 24.244 | 12.451 | 11.790 | 10.062 |
| Total Expenses - EUR | - | - | - | - | - | 7.291 | 13.642 | 10.002 | 12.428 | 13.717 |
| Gross Profit/Loss - EUR | - | - | - | - | - | -547 | 10.602 | 2.449 | -638 | -3.655 |
| Net Profit/Loss - EUR | - | - | - | - | - | -611 | 10.364 | 2.343 | -750 | -3.751 |
| Employees | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Maysel - Anaflav S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | - | - | 244 | 10.356 | 12.698 | 5.715 | 2.561 |
| Inventories | - | - | - | - | - | 6 | 932 | 2.557 | 2.347 | 2.191 |
| Receivables | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cash | - | - | - | - | - | 238 | 9.424 | 10.142 | 3.368 | 370 |
| Shareholders Funds | - | - | - | - | - | -611 | 9.807 | 12.181 | 4.985 | 1.207 |
| Social Capital | - | - | - | - | - | 0 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 854 | 548 | 518 | 729 | 1.354 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4779 - 4779" | |||||||||
| CAEN Financial Year |
4779
|
|||||||||
Comments - Maysel - Anaflav S.r.l.